SCHEMBL480184

SCHEMBL480184

Cn1cc(C(=O)O)cc(Cl)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.45
TSHR P16473 1/20 0.44
KMT2A Q03164 3/20 0.42
CYP2C9 P11712 2/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 1/20 0.42
TPMT P51580 2/20 0.40
SRD5A2 P31213 1/20 0.39
RAB9A P51151 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
CREBBP Q92793 2/20 0.37
BRD4 O60885 2/20 0.35
P2RX7 Q99572 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
PLAU P00749 1/20 0.35
BRD9 Q9H8M2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217732 0.80 CYP1A2 (0.46) KMT2ACYP2C9CA12CA1CA9
SCHEMBL480606 0.78 BRD4 (0.50) BRD4BRD9
SCHEMBL10941908 0.78 TPMT (0.43) TTRTSHRKMT2ACYP2C9MEN1
SCHEMBL2260637 0.77 TTR (0.45) TTRKMT2ACYP2C9TPMTCREBBP
SCHEMBL21383990 0.77 LMNA (0.41) TTRKMT2AMEN1TPMTRAB9A
SCHEMBL15228321 0.77 TPMT (0.47) KMT2ACYP2C9MEN1POLBTPMT
SCHEMBL3165877 0.77 P2RX7 (0.44) TTRTSHRKMT2AMEN1POLB
SCHEMBL3163591 0.76 CREBBP (0.44) KMT2AMEN1POLBRAB9ACREBBP
SCHEMBL29092189 0.74 BRD4 (0.43) KMT2ACYP2C9MEN1POLBRAB9A
SCHEMBL16512169 0.74 CREBBP (0.35) KMT2ACYP2C9MEN1POLBTPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 US claimed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 CN claimed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP claimed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 US claimed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO claimed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 US claimed
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
EP-4041229-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114727991-A Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-08 CN disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
EP-3060549-B1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE DAE WOONG PHARMA (KR) 2019-02-13 EP disclosed
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 US disclosed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 CN disclosed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 EP disclosed
US-6869966-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 US disclosed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 US disclosed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO disclosed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 TTR 2853/4885TSHR 1969/4885KMT2A 229/4885
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders NPY1R, NPY2R, NPY4R TTR 3438/4885TSHR 139/4885KMT2A 3391/4885
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives GPR119, NPY4R, NPY1R TTR 3880/4885TSHR 152/4885KMT2A 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.